IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2161 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (879 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 »  Abstract
 » Introduction
 » Possible Targets
 »  Mental Stressors...
 » Discussion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed295    
    Printed4    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
POTENTIAL PHARMACOLOGICAL TARGETS
Year : 2020  |  Volume : 52  |  Issue : 3  |  Page : 222-226
 

Target/therapies for chronic recurrent erythema nodosum leprosum


1 Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
2 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

Date of Submission12-Dec-2019
Date of Decision12-Feb-2020
Date of Acceptance25-Mar-2020
Date of Web Publication4-Aug-2020

Correspondence Address:
Dr. Pugazhenthan Thangaraju
Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.IJP_788_19

Rights and Permissions

 » Abstract 


A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and the mental stressors for the possible management strategies.


Keywords: Antidiabetic, erythema nodosum leprosum, lepra reaction, pharmacology, stress, targets


How to cite this article:
Thangaraju P, Varthya SB, Venkatesan S. Target/therapies for chronic recurrent erythema nodosum leprosum. Indian J Pharmacol 2020;52:222-6

How to cite this URL:
Thangaraju P, Varthya SB, Venkatesan S. Target/therapies for chronic recurrent erythema nodosum leprosum. Indian J Pharmacol [serial online] 2020 [cited 2020 Sep 18];52:222-6. Available from: http://www.ijp-online.com/text.asp?2020/52/3/222/291395





 » Introduction Top


Erythema nodosum leprosum (ENL) is a troublesome, and difficult to manage immunological entity seen in bacilli positive intermediate borderline lepromatous and the polar lepromatous leprosy. ENL presents both as acute or chronic episodes. The acute episodes occur at multiple time point till the bacilli are removed from the body.[1],[2] In an indian cohort study, only <10% of patients had a single episode, while around 62.5% had chronic occurring ENL.[2] Various manifestations of ENL include generalized, cutaneous, and peripheral nerve involvement. The name derived from its cutaneous manifestations that occurred as a widespread crops of lesions that are erythematous, inflamed subcutaneous nodules, and/or papules. They appear superficially or rarely deep that weans off periodically.[3] The severe forms such as bullous, pustular, ulcerated, and necrotic forms have also been routinely described. ENL nodules in several circumstances lead to fibrosis that causes irreversible scarring.[3] The nerve involved sometimes present with painful may be enlarged with functional impairment. The ENL patients mostly present with generalized illness due to immune complex activation causing high-grade fever and toxemia. Transient proteinuria and edema of hands and feet may also occur in the severe category. In the eye, iridocyclitis can occur in some cases and may be sight-threatening and early intervention is always mandatory.[3] The other findings such as scrotal swelling, hepatomegaly, splenomegaly, lymph node involvement, polyarthritis, and inflammation of the fingers with osteoporosis are well-recognized and documented.


 » Possible Targets Top


The areas for the possible targets include the mental stressors and the inflammatory mediators [Figure 1].
Figure 1: Possible targets

Click here to view


Inflammatory mediators as targets

Various serological markers have been identified in the pathology of ENL reaction. This includes tumor necrosis factor alpha (TNF-α), interleukins (IL-6, IL-7, and IL-17F), matrix metallopeptidases-9, phenolic glycolipids-1, chemokine ligand-11, and alpha-1-acid glycoprotein[4] [Table 1].
Table 1: Inflammatory mediators and drugs that are tried and could be

Click here to view


Tumor necrosis factor alpha inhibition

The most important mechanism by which steroids and thalidomide act is, through the inhibition of TNF-α, which are found in high levels in inflammation seen in ENL reactions [Figure 2].
Figure 2: Overview of metformin hypothesis

Click here to view


Old wine in new bottle (metformin for erythema nodosum leprosum)

Metformin as an anti-inflammatory (tumor necrosis factor-alpha inhibition)-In cell cultures

Manyin vitro studies [Table 2] proved the anti-inflammatory action of metformin focusing on TNF-α inhibition. These inhibitory effects were mediated through different pathways. The various pathways showing inhibition of TNF-α are mammalian target of rapamycin – signaling pathway in human keratinocytes in psoriasis,[5] Activating ATF3 induction in murine macrophage,[6] inhibiting early inflammatory mediators of human monocytes growth response factor 1[7] and inhibiting nuclear factor-kappa b (NF-κb) in endothelial cells.[8]
Table 2: In vivo and in vitro evidences

Click here to view


In animal experiments

Manyin vivo studies [Table 2] also demonstrated the inhibitory role of metformin on tumor necrosis factor alpha claiming its anti-inflammatory role. The anti-inflammatory effects of metformin have been shown in a Wistar rat model of myocardial infarction where left ventricular dysfunction occurs due to myocardial inflammation and the same is reduced by metformin,[9] reduction of inflammation in murine autoimmune arthritis[10] and also in endotoxemic mice.[12]

Clinical studies

In recent years, around eight studies [Table 3] have shown the inhibitory role of metformin on TNF-α when they were either given as monotherapy[13],[17],[18],[19],[20] or in combination with other drugs.[14],[16] The results have also shown a direct inhibitory potential in respect to dose and duration.
Table 3: Clinical studies showing inhibitory action of metformin on tumor necrosis factor alpha

Click here to view



 » Mental Stressors as Target Top


The most common precipitating factors for the development of lepra reactions are well established in literatures include vaccinations, infections, multidrug therapy for leprosy, and psychological stress.[21],[22] The role of the psychological component is not much evaluated by interventional drug during the management of reactions.

Physiology of mental stressors

It is very well-established that mental stressors in reaction patients cause activation of two important neural pathways. The one being the hypothalamic-pituitary-adrenal axis, and the another is the autonomic system. The sympathetic nervous system contributes the maximum causing the neurogenic inflammation.[23] The cutaneous structure is an important component of this established neuro-immunocutaneous-endocrine system and the emotional disturbances as reflected by anxiety and psychological distress can significantly alter the immunological status of the patient leading to intense reactions.[24]

Drug targets

Hence, a group of drugs targeting these mental stressor could be a good strategy to prevent the occurrences of recurrent reactions and to break the vicious cycle triggering these recurrences [Figure 1]. This helps the patients from not exposing frequently to the ill effects of anti-reactions drugs which are with major adverse effects.

Selective serotonin re-uptake inhibitors

In this respect, the drug “Selective Serotonin Re-uptake inhibitors, (SSRI's)” could be a good pharmacological interventions in preventing the recurrence of lepra reactions. In the brain, the neuronal communication happens through the chemical synapse. There are two types of regions, namely the presynaptic and postsynaptic region/cells. The presynaptic cell which releases neurotransmitters namely serotonin into the junctional gap once the signal is received. The serotonin acts on their respective receptors present on the surface of the postsynaptic cell and causes the stimulation and other underlying molecular mechanisms. During this process, almost 90% of serotonin is released from the postsynaptic receptors into the cleft and once again taken up into the presynaptic neurons by the monoamine transporters by a process of reuptake. SSRIs drugs inhibit the process of this reuptake and increase the concentration of serotonin in the synaptic cleft and helps in postsynaptic receptor stimulations.

SSRI's are a group of anti-depressants, often prescribed for depression and generalized anxiety disorder because they are safe and well tolerated.[13],[15],[17]

Selective serotonin re-uptake inhibitor's - anti-inflammatory

The anti-inflammatory properties of SSRI were not only on the peripheral immune cells but also centrally on microglial cells that respond to various signals of inflammatory factors. A study by Tynan et al.,[25] evaluated the efficacy of five different SSRIs in assessing the suppression property of the drugs to a various inflammatory stimulus. The drugs, namely citalopram, sertraline, fluoxetine, fluvoxamine, and paroxetine along with one other group of SNRI drug were used. They found its role in the suppression of microglial inflammation in response to inflammatory stimulus The study also examined their ability to alter TNF-α and found its potential in the inhibition of microglial tumor necrosis factor-α and suggesting that antidepressants have therapeutic effectiveness to their anti-inflammatory properties also. As the recent evidences also pile up with SSRI's for its additional anti-inflammatory benefits,[26] it could be a good therapeutic strategy in treating both the mental stressor as well as the reaction inflammations.


 » Discussion Top


ENL occurs due to immune complex mediated-complement system activation. In general, in response to various stimuli, the immune cells release both the cytokines, pro-inflammatory as well as the anti-inflammatory.[20] Macrophages are activated by pro-inflammatory cytokines that promote inflammation. The anti-inflammatory cytokines help in balancing the immune system by preventing the hazardous effect of inflammation caused by pro-inflammatory cytokines.[27],[28]

In a study by Hyun et al., our hypothesized drug metformin reduced the production of cytokines, namely IL (IL-1β, IL-6, TNF-α) in a dose-dependent manner and by the inhibition of protein and messenger RNA expression. In addition to its inhibiting properties, the anti-inflammatory cytokines, namely IL-4 and IL-10 protein expression were also be upregulated, and it is maintained throughout.[29] Hence, the drug metformin can be used in an ENL reaction with dual benefit in a dose-dependent manner.

Circulating monocytes are attracted by chemokine and by various adhesion molecules, namely selectin (E and P), vascular cell adhesion molecule 1, intercellular adhesion molecule 1, that were expressed by endothelial cells on stimulation by TNF-α.[30] There occurs an increase in an inflammatory response which is caused by Monocyte-derived macrophages and vascular endothelial cells by the release of various chemoattractants and the cytokines in pro-inflammation.[31],[32] These migrations of monocytes from the systemic vascular compartment to the site of inflammation can be inhibited by metformin.

The transcription factor namely NF-κB plays a vital role in the orchestra of various inflammatory responses. Metformin exerts its anti-inflammation in a dose-dependent manner. It reduces the synthesis of all pro-inflammatory cytokines through the suppression of IκBα phosphorylation and also the translocation of NF-κB mainly the protein p65 from the cytoplasm to the core nucleus.[29] In pregnancy also metformin can be used safely.

Prednisolone and thalidomide have been used in ENL to suppress the severity of clinical manifestations and to provide remission. Being drugs with major side-effects, the plan for the use of alternative drugs for the treatment of ENL that down-regulate TNF production should be a logical approach in the management of reaction. In this regard, metformin seems to be safe in all the age groups and can be used for a longer duration.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 2004;72:125-33.  Back to cited text no. 1
    
2.
Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: An 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006;74:868-79.  Back to cited text no. 2
    
3.
Thangaraju P, Selvam T, Ali MK. Metformin, an antidiabetic drug as a therapeutic agent in the treatment of moderate to severe chronic erythema nodosum leprosum. Fontilles Rev leprol 2016;30:479-90.  Back to cited text no. 3
    
4.
Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol Leprol 2013;79:739-49.  Back to cited text no. 4
[PUBMED]  [Full text]  
5.
Liu Y, Yang F, Ma W, Sun Q. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytesin vitro via mTOR-signaling pathway. Pharm Biol 2016;54:1173-8.  Back to cited text no. 5
    
6.
Kim J, Kwak HJ, Cha JY, Jeong YS, Rhee SD, Kim KR, et al. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J Biol Chem 2014;289:23246-55.  Back to cited text no. 6
    
7.
Arai M, Uchiba M, Komura H, Mizuochi Y, Harada N, Okajima K. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J Pharmacol Exp Ther 2010;334:206-13.  Back to cited text no. 7
    
8.
Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006;47:1183-8.  Back to cited text no. 8
    
9.
Soraya H, Clanachan AS, Rameshrad M, Dizaji NM, Khansari MG, Garjani A. Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. Eur J Pharmacol 2014;737:77-84.  Back to cited text no. 9
    
10.
Kang KY, Kim YK, Yi H, Kim J, Jung HR, Kim IJ, et al. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. Int Immunopharmacol 2013;16:85-92.  Back to cited text no. 10
    
11.
Tsoyi K, Jang HJ, Nizamutdinova IT, Kim YM, Lee YS, Kim HJ, et al. Metformin inhibits HMGB1 release in LPS-treated RAW264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 2011;162:1498-508.  Back to cited text no. 11
    
12.
Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158:631-41.  Back to cited text no. 12
    
13.
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95.  Back to cited text no. 13
    
14.
Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: A 12-month, placebo-controlled study. Expert Opin Pharmacother 2012;13:2581-91.  Back to cited text no. 14
    
15.
Krysiak R, Okopien B. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis 2012;225:403-7.  Back to cited text no. 15
    
16.
McCoy RG, Irving BA, Soop M, Srinivasan M, Tatpati L, Chow L, et al. Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. Mayo Clin Proc 2012;87:561-70.  Back to cited text no. 16
    
17.
Yu S, Zhang Y, Li MZ, Xu H, Wang Q, Song J, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J (Engl) 2012;125:3440-4.  Back to cited text no. 17
    
18.
Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, et al. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Intern Med 2013;52:2179-87.  Back to cited text no. 18
    
19.
Xu W, Deng YY, Yang L, Zhao S, Liu J, Zhao Z, et al. Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction. Transl Res 2015;166:451-8.  Back to cited text no. 19
    
20.
Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503-8.  Back to cited text no. 20
    
21.
Kar HK, Sharma P. Leprosy reactions. In: Kar HK, Kumar B, editors. IAL Text Book of Leprosy. 1st ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2010. p. 269-89.  Back to cited text no. 21
    
22.
Pfaltzgraff RE, Ramu G. Clinical leprosy. In: Hastings RC, editor. Leprosy. 2nd ed. New York: Churchill Livingstone; 1994. p. 237-87.  Back to cited text no. 22
    
23.
Harth W, Gieler W, Kusnir D, Tausk FA, editors. Clinical Management in Psychodermatology. 1st ed. Berlin, Heidelberg: Springer Verlag; 2009.  Back to cited text no. 23
    
24.
Latheef EA, Riyaz N. Hypnotherapy: A useful adjunctive therapeutic modality in Hansen's disease. Indian J Dermatol 2014;59:166-8.  Back to cited text no. 24
    
25.
Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012;26:469-79.  Back to cited text no. 25
    
26.
Walker FR. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology 2013;67:304-17.  Back to cited text no. 26
    
27.
Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A 2006;103:2274-9.  Back to cited text no. 27
    
28.
Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000;117:1162-72.  Back to cited text no. 28
    
29.
Hyun B, Shin S, Lee A, Lee S, Song Y, Ha NJ, et al. Metformin down-regulates TNF-α Secretion via suppression of scavenger receptors in macrophages. Immune Netw 2013;13:123-32.  Back to cited text no. 29
    
30.
Skoog T, Dichtl W, Boquist S, Andersson CS, Karpe F, Tang R, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002;23:376-83.  Back to cited text no. 30
    
31.
Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: A comprehensive review of studies in mice. Cardiovasc Res 2008;79:360-76.  Back to cited text no. 31
    
32.
Mei CL, Chen ZJ, Liao YH, Wang YF, Peng HY, Chen Y. Interleukin-10 inhibits the down-regulation of ATP binding cassette transporter A1 by tumour necrosis factor-alpha in THP-1 macrophage-derived foam cells. Cell Biol Int 2007;31:1456-61.  Back to cited text no. 32
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow